Pfizer’s Mylotarg is back ... after the FDA reapproved it in the aggressive blood cancer, acute myeloid leukaemia. The world’s first approved antibody-drug conjugate, where a targeted antibody ...

The company said the discontinuation was due to several reasons,” Reuters news service reported, “including limited interest in gene therapies for the bleeding disorder.” (Pfizer had earlier dumped a ...

U.S. Food and Drug Administration. "FDA Approves First COVID ... of Adults and Adolescents with Hemophilia A or B Without Inhibitors." Edgar Online. "Pfizer Inc. Schedule 14A, Proxy Statement ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...